Subscribe To
Intellia's (ntla) ind for gene-editing therapy gets fda clearance
Intellia (NTLA) gets FDA nod to begin a phase iii study on its gene editing candidate, NTLA-2001 to tre...
October 19, 2023, 12:47 pm
Annovis (anvs) ad study to continue as planned, shares rise
Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/iii ...
October 13, 2023, 2:16 pm
Biocardia (bcda) up on plans for second heart failure study
BioCardia (BCDA) completes enrollment in a pivotal phase iii study on its CardiAMP cell therapy for the...
October 12, 2023, 12:47 pm
Roche's (rhhby) vabysmo positive in late-stage rvo studies
Roche (RHHBY) Vabysmo maintains vision improvements with extended treatment intervals of up to four months in phase ...
October 10, 2023, 1:32 pm
Novartis (nvs) announces positive data on kidney disease drug
Novartis' (NVS) phase iii study on pipeline candidate iptacopan in patients with IgAN shows superiority...
October 3, 2023, 1:32 pm
Roche to present new key clinical and real-world data at ectrims-actrims 2023 showcasing strength of long-term outcomes in ms and nmosd
Basel, 02 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new data for OCREVUS® (ocrelizumab) and investigational Bruton's tyrosine ki...
October 2, 2023, 1:00 am
Baudax bio shares rocket as lead clinical candidate gains fda orphan drug designation
Shares of Baudax Bio added 80% after it announced its lead clinical candidate targeting Hemophilia A with inhibitors has been awarded orphan drug stat...
September 28, 2023, 12:27 pm
Novartis (nvs) lutathera meets primary goal in phase iii study
Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line adva...
September 25, 2023, 1:32 pm
Jazz pharma (jazz) gets eu nod for cancer drug enrylaze
The approval is based on data from a phase II/iii study, which showed that treatment with Jazz's (JAZZ)...
September 22, 2023, 1:31 pm
Relmada (rlmd) up on positive data for anti-depressant candidate
Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase iii study of its le...
September 21, 2023, 3:02 pm
Cymabay (cbay) stock up on positive results from pbc study
CymaBay (CBAY) reports encouraging data from the phase iii study of seladelpar in PBC patients. Stock u...
September 8, 2023, 2:17 pm
G-iii apparel stock soars after a big earnings beat, license deal to produce champion outerwear
Shares of G-III Apparel Group Ltd. Giii shot up 14.8% toward a 13-month high in premarket trading Thurs...
September 7, 2023, 7:43 am
Biocardia (bcda) dips 26% on flunking heart failure study
Based on one-year follow-up data from a pivotal phase iii study, BioCardia (BCDA) reveals that its Card...
September 6, 2023, 12:01 pm
Marijuana's reclassification is 'long overdue' by the dea: curaleaf ceo
Following urgings by the U.S. Department of Health & Human Services, DEA officials could reclassify marijuana's drug status to that of a Schedule
September 4, 2023, 10:00 am
Pot stocks rally after health officials ask dea to reclassify marijuana as lower-risk drug
Assistant Secretary for Health Rachel Levine reportedly requested in a letter to DEA Administrator Anne Milgram that marijuana be downgraded to a sche...
August 30, 2023, 4:56 pm
Kodiak (kod) down as late-stage dme studies fail
Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase iii studies evaluating ta...
July 25, 2023, 10:53 am
Curium announces publication of [18f]dcfpyl versus [18f]fluoromethylcholine results from european phase iii study (python trial)
PARIS, July 21, 2023 (GLOBE NEWSWIRE) — Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, ...
July 21, 2023, 7:30 am
Lilly's (lly) donanemab slows alzheimer's disease progression
Data from a phase iii study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and ...
July 18, 2023, 12:50 pm
Seelos: 2 catalysts before end of 2023 make this a must watch
Results from Part 2 of the phase 2 registration-directed study, using SLS-002 for acute suicidal ideation and behavior for MDD, are expected to be rel...
July 12, 2023, 7:09 pm
Incyte's (incy) opzelura meets goal in phase iii pediatric study
Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase iii study in childre...
July 12, 2023, 12:34 pm